Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion type Assertion NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_head.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion evidence source_evidence_literature NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion SIO_000772 23720052 NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion wasDerivedFrom befree-20150227 NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.
- NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion wasGeneratedBy ECO_0000203 NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.